Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Iloperidone Depot Formulations in Schizophrenia
NCT01348100Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iloperidone in schizophrenia (7 arms), sponsored by Novartis. Primary endpoints: Maximum Observed Plasma Concentration Divided by Average Plasma Concentration and Average Plasma Concentration. Started Apr 2011; status: completed.
02
Drugs
iloperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01348100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01348100.